Kidney Research Center, Department of Nephrology, Chang Gung Memorial Hospital, Linkou branch, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
PLoS One. 2018 Sep 4;13(9):e0203447. doi: 10.1371/journal.pone.0203447. eCollection 2018.
Although urinary neutrophil gelatinase-associated lipocalin (NGAL) has emerged as a promising biomarker for the early detection of kidney injury, previous studies of adult patients who underwent cardiac surgery have reported only moderate discrimination. The age, creatinine, and ejection fraction (ACEF) score is a preoperative validated risk model with satisfactory accuracy for predicting AKI following cardiac surgery. It remains unknown whether combining preoperative risk assessment through ACEF scores followed by urinary NGAL test in a population of high-risk individuals is an optimal approach with improved predictive performance.
A total of 177 consecutive patients who underwent cardiac surgery were enrolled. Clinical characteristics, prognostic model scores, and outcomes were assessed. Urinary NGAL were examined within 6 hours after cardiac surgery. Patients were stratified according to preoperative ACEF scores, and comparisons were made using the area under the receiver operator characteristic curve (AUROC) for the prediction of AKI.
A total of 45.8% (81/177) of the patients had AKI. As expected, patients with ACEF scores ≥ 1.1 were older and more likely to have class III or IV heart failure. They were also more likely to have diabetes mellitus, myocardial infarction, and peripheral arterial disease. Urinary NGAL alone moderately predicted AKI, with an AUROC of 0.732. Risk stratification by ACEF scores ≥ 1.1 substantially improved the AUROC of urinary NGAL to 0.873 (95% confidence interval, 0.784-0.961; P < .001).
Risk stratification by preoperative ACEF scores ≥ 1.1, followed by postoperative urinary NGAL, provides more satisfactory risk discrimination than does urinary NGAL alone for the early detection of AKI after cardiac surgery. Future studies should investigate whether this strategy could improve the outcomes and cost-effectiveness of care in patients undergoing cardiac surgery.
尽管尿中性粒细胞明胶酶相关脂质运载蛋白(NGAL)已成为早期检测肾损伤的一种很有前途的生物标志物,但之前对接受心脏手术的成年患者的研究仅显示出中度的鉴别能力。ACEF 评分(年龄、肌酐和射血分数)是一种术前验证的风险模型,用于预测心脏手术后 AKI 具有令人满意的准确性。尚不清楚在高危人群中,通过 ACEF 评分进行术前风险评估,然后结合尿 NGAL 检测,是否是一种具有改善预测性能的优化方法。
共纳入 177 例连续接受心脏手术的患者。评估了临床特征、预测模型评分和结局。在心脏手术后 6 小时内检测尿 NGAL。根据术前 ACEF 评分对患者进行分层,并使用接受者操作特征曲线下面积(AUROC)比较预测 AKI 的效果。
共有 45.8%(81/177)的患者发生 AKI。正如预期的那样,ACEF 评分≥1.1 的患者年龄较大,更有可能患有 III 或 IV 级心力衰竭。他们也更有可能患有糖尿病、心肌梗死和外周动脉疾病。单独使用尿 NGAL 可适度预测 AKI,AUROC 为 0.732。通过 ACEF 评分≥1.1 进行风险分层可显著提高尿 NGAL 的 AUROC 至 0.873(95%置信区间,0.784-0.961;P<.001)。
通过术前 ACEF 评分≥1.1 进行风险分层,然后结合术后尿 NGAL,可以比单独使用尿 NGAL 更准确地预测心脏手术后 AKI 的早期发生。未来的研究应探讨这种策略是否可以改善接受心脏手术患者的结局和成本效益。